Progress and Harmonization of Gene Editing to Treat Human Diseases (Proceeding of COST Action CA21113 GenE-HumDi)
Résumé
The European Cooperation in Science and Technology (COST) is an intergovernmental
organization dedicated to funding and coordinating scientific and technological
research in Europe, fostering collaboration among researchers and institutions across
countries. Recently, COST Action funded the "Genome Editing to treat Human
Diseases" (GenE-HumDi) network, uniting various stakeholders such as pharmaceutical
companies, academic institutions, regulatory agencies, biotech firms, and patient
advocacy groups. GenE-HumDi's primary objective is to expedite the application of
genome editing for therapeutic purposes in treating human diseases. To achieve this
goal, GenE-HumDi is organized in several working groups, each focusing on specific
aspects. These groups aim to enhance genome editing technologies, assess delivery
systems, address safety concerns, promote clinical translation, and develop regulatory
guidelines. The network seeks to establish standard procedures and guidelines for
these areas to standardize scientific practices and facilitate knowledge sharing.
Furthermore, GenE-HumDi aims to communicate its findings to the public in accessible
yet rigorous language, emphasizing genome editing's potential to revolutionize the
treatment of many human diseases. The inaugural GenE-HumDi meeting, held in
Granada, Spain, in March 2023, featured presentations from experts in the field,
discussing recent breakthroughs in delivery methods, safety measures, clinical
translation, and regulatory aspects related to gene editing.
Origine | Fichiers produits par l'(les) auteur(s) |
---|